Dr. Reddy's Laboratories Limited (NSE:DRREDDY)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Pharmaceutical Services and Active Ingredients (PSAI)	42.04B	43.24B	40.58B	36.52B	30.74B
Pharmaceutical Services and Active Ingredients (PSAI) Growth	-2.76%	6.54%	11.12%	18.80%	-20.95%
Global Generics	299.03B	289.55B	245.45B	213.77B	179.17B
Global Generics Growth	3.27%	17.97%	14.82%	19.31%	21.47%
Others	2.13B	2.14B	3.91B	3.04B	4.48B
Others Growth	-0.47%	-45.35%	28.53%	-32.11%	34.32%
Inter-Segment Revenues	-7.27B	-9.39B	-10.78B	-7.45B	-
Total	335.93B	325.54B	279.16B	245.88B	214.39B
Total Growth	3.19%	16.61%	13.54%	14.69%	13.00%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
North America	113.74B	-	-	-	-
Europe	55.50B	-	-	-	-
India	62.19B	55.83B	48.47B	50.50B	43.99B
India Growth	11.38%	15.18%	-4.01%	14.81%	21.33%
Emerging Markets	67.61B	-	-	-	-
Unallocated	34.77B	-	-	-	-
Others	2.13B	94.40B	72.83B	67.47B	68.96B
Others Growth	-97.75%	29.62%	7.94%	-2.16%	13.14%
United States	-	149.35B	135.57B	106.68B	80.56B
United States Growth	-	10.17%	27.07%	32.42%	5.04%
Russia	-	25.96B	22.30B	21.23B	20.88B
Russia Growth	-	16.40%	5.05%	1.67%	32.01%
Total	335.93B	325.54B	279.16B	245.88B	214.39B
Total Growth	3.19%	16.61%	13.54%	14.69%	13.00%

Source: S&P Global Market Intelligence.